Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation

International Journal of Hematology

Volumn 82, Issue 4, 2005, Pages 362-366

  Inamoto, Yoshihiro ^a   Teramoto, Tamio ^b   Shirai, Koji ^c   Tsukamoto, Hideko ^d   Sanda, Takaomi ^a   Miyamura, Koichi ^a   Yamamori, Ikuo ^a   Hirabayashi, Noriyuki ^a   Kodera, Yoshihisa ^a  

^a JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^b TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Allogeneic transplantation; Hepatic triglyceride lipase (HTGL); Hypercholesterolemia; Lipoprotein X (Lp X); Lipoprotein Y (Lp Y)

Indexed keywords

BEZAFIBRATE; CHOLESTEROL; LIPOPROTEIN; LIPOPROTEIN X; LIPOPROTEIN Y; PREDNISONE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BILE DUCT DISEASE; CASE REPORT; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; HYPERCHOLESTEROLEMIA; HYPONATREMIA; PSEUDOHYPONATREMIA;

ABO BLOOD-GROUP SYSTEM; ADULT; BLOOD GROUP INCOMPATIBILITY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPONATREMIA; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIPASE; LIVER; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 33644676664     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05064     Document Type: Article

References (26)

1. Rosenson RS, Baker AL, Chow MJ, Hay RV. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology. 1990;98:1351-1357.
2. Kuster GM, Drexel H, Bleisch JA, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 1994;57:1479-1483.
3. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 2000;16:505-511.
4. Manzato E, Fellin R, Baggio G, Walch S, Neubeck W, Seidel D. Formation of lipoprotein-X. Its relationship to bile compounds. J Clin Invest. 1976;57:1248-1260.
5. Watanabe M. Lipoprotein abnormalities in cholestasis. I. Electrophoretic and ultracentrifugal analyses. Acta Med Okayama. 1979;33:269-285.
6. Miller JP. Dyslipoproteinaemia of liver disease. Baillieres Clin Endocrinol Metab. 1990;4:807-832.
7. Koga S, Miyata Y, Ibayashi H. Plasma lipoproteins and apoproteins in primary biliary cirrhosis. Hepatology. 1985;5:286-292.
8. Strasser SI, Shulman HM, McDonald GB. Cholestasis after hematopoietic cell transplantation. Clin Liver Dis. 1999;3:651-668, x.
9. Turchin A, Seifter JL, Seely EW. Clinical problem-solving. Mind the gap. N Engl J Med. 2003;349:1465-1469.
10. Abe M, Kawano M, Tashiro T, et al. Catabolism of lipoprotein-X induced by infusion of 10% fat emulsion. Nutrition. 1997;13:417-421.
11. Chang PY, Lu SC, Su TC, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res. 2004;45:2116-2122.
12. Goldberg IJ, Mazlen RG, Rubenstein A, et al. Plasma lipoprotein abnormalities associated with acquired hepatic triglyceride lipase deficiency. Metabolism. 1985;34:832-835.
13. Breckenridge WC, Little JA, Alaupovic P, et al. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atherosclerosis. 1982;45:161-179.
14. Carlson LA, Holmquist L, Nilsson-Ehle P. Deficiency of hepatic lipase activity in post-heparin plasma in familial hyper-alphatriglyceridemia. Acta Med Scand. 1986;219:435-447.
15. Klose G, Windelband J, Weizel A, Greten H. Secondary hypertriglyceridaemia in patients with parenchymal liver disease. Eur J Clin Invest. 1977;7:557-562.
16. Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology. 1985;89:1266-1278.
17. Colvin PL Jr, Auerbach BJ, Case LD, Hazzard WR, Applebaum-Bowden D. A dose-response relationship between sex hormone-induced change in hepatic triglyceride lipase and high-density lipoprotein cholesterol in postmenopausal women. Metabolism. 1991;40:1052-1056.
18. Nishimura M, Ohkaru Y, Ishii H, Sunahara N, Takagi A, Ikeda Y. Development and evaluation of a direct sandwich-enzyme-linked immunosorbent assay for the quantification of human hepatic triglyceride lipase mass in human plasma. J Immunol Methods. 2000;235:41-51.
19. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl. 1999;71:S22-24.
20. Connelly PW, Hegele RA. Hepatic lipase deficiency. Crit Rev Clin Lab Sci. 1998;35:547-572.
21. Moennig G, Wiebusch H, Enbergs A, et al. Detection of missense mutations in the genes for lipoprotein lipase and hepatic triglyceride lipase in patients with dyslipidemia undergoing coronary angiography. Atherosclerosis. 2000;149:395-401.
22. Coakley JC, Vervaart PP, McKay MR. Factitious hyponatremia in a patient with cholestatic jaundice following bone marrow transplantation. Pathology. 1986;18:158-159.
23. Turchin A, Wiebe DA, Seely EW, Graham T, Longo W, Soiffer R. Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant. 2005;35:85-89.
24. Toren A, Nagler A. Solitary pulmonary cholesteroloma, multiple xanthelasmas and lipemia retinalis complicating hypercholesterolemia after bone marrow transplantation. Bone Marrow Transplant. 1996;18:457-459.
25. Tallet F, Vasson MP, Couderc R, Lefevre G, Raichvarg D. Characterization of lipoproteins during human cholestasis. Clin Chim Acta. 1996;244:1-15.
26. O'Kane MJ, Lynch PL, Callender ME, Trimble ER. Abnormalities of serum apo A1 containing lipoprotein particles in patients with primary biliary cirrhosis. Atherosclerosis. 1997;131:203-210.